Results 131 to 140 of about 50,863 (305)

Ixekizumab Retention Rate and Predictors of Treatment Persistence in Psoriatic Arthritis: Results of an Italian Multicenter Study [PDF]

XE (Ixekizumab) is a monoclonal antibody targeting interleukin-17A (IL17A) which has demonstrated significant efficacy and safety in the management of psoriatic arthritis (PsA) in randomized controlled trials (RCTs).
Antonella Farina, Bernd Raffeiner, Fabio Mascella, Eleonora Celletti, Myriam Di Penta, Dario Camellino, Maddalena Larosa, Francesco Colella Molica, Francesca Serale, Gianluca Smerilli, Rosalba Caccavalle, Eleonora Di Donato, Camilla Mazzanti, Mirco Magnani, Francesco De Lucia, Gerolamo Bianchi, Gianluca Lucchini, Olga Addimanda, Giulio Ferrero, Claudio Angrisani, Emanuela Sabatini, Marino Paroli, Roberta Foti, Elisa Visalli, Natalia Mansueto, Patrizia Del Medico, Aldo Biagio Colella Molica, Rosetta Vitetta, Alberto Lo Gullo, Francesca Ometto, Elena Bravi, Guido Rovera, Dilia Giuggioli, Valeria Nucera, Massimo Reta, Federica Lumetti, Antonio Marchetta, Carlo Salvarani, Vincenzo Bruzzese, Andrea Becciolini, Davide Murgia, Giuditta Adorni, Giorgio Amato, Alessandra Bezzi, Viviana Ravagnani, Alessandro Volpe, Simone Bernardi, Veronica Franchina, Daniele Santilli, Eugenio Arrigoni, Ilaria Platè, Simone Parisi, Alarico Ariani, Ylenia Dal Bosco, Marta Priora, Palma Scolieri, Massimiliano De Simone, Rosario Foti, Gianluca Santoboni, Romina Andracco, Pietro Del Biondo, Francesco Girelli, Cecilia Giampietro, Enrico Fusaro, Gilda Sandri, Maria Chiara Ditto, Aurora Ianniello   +66 more
core   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

British Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun, Jingrong Yang, Lei Wan, Xia Xu, Jing Wang   +4 more
wiley   +1 more source

Cardiovascular risk assessment and management in rheumatoid arthritis : are guidelines being followed? [PDF]

, 2014
Aim: The aim of the audit was to determine whether the cardiovascular risk assessment and management in rheumatoid arthritis patients at Mater Dei Hospital is in concordance with the recommendations by the European League Against Rheumatism (EULAR ...
Borg, Andrew A., Magro, Rosalie, Buhagiar, Malcolm, Taliana, Nikita   +3 more
core  

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Ten‐Year Public Expenditure Savings Associated with TNF Inhibitor Biosimilars under Australia's Pharmaceutical Benefits Scheme

Clinical Pharmacology &Therapeutics, EarlyView.
Biologic therapies are a major and growing driver of pharmaceutical expenditure globally, with tumor necrosis factor (TNF) inhibitors among the most widely used and costly biologics. In Australia, these therapies are funded through the Pharmaceutical Benefits Scheme (PBS), where biosimilars offer lower cost alternatives; however, the long‐term public ...
Chin Hang Yiu, Bella D. Ianni, Richard O. Day, Jacques Raubenheimer, Christine Y. Lu   +4 more
wiley   +1 more source

Hematological Inflammation Indices Are Associated With Active Uveitis in Ankylosing Spondylitis

Journal of Clinical Laboratory Analysis, EarlyView.
Hematological inflammation indices reflect the systemic inflammatory burden in ankylosing spondylitis. Patients with active uveitis exhibit a distinct pro‐inflammatory profile characterised by increased NLR, PLR, SII, SIRI, and AISI, along with decreased HALP and CALLY scores.
Mesude Seda Aydoğdu, Zarife Ekici Gök
wiley   +1 more source

Alterations in brain metabolites in rats with experimental periodontitis: A metabolomic approach

Journal of Periodontology, EarlyView.
Abstract Background Periodontitis (PD) is a chronic inflammatory disease with systemic effects. Emerging evidence suggests a link between periodontal inflammation and neurological changes, but the biochemical mechanisms in key brain regions, such as the hippocampus and amygdala, remain unclear.
Ramona Ramalho de Souza Pereira, Caíque Olegário Diniz e Magalhães, Elizabeth Luciana Marinho Miguel, Larissa Vieira Toledo, Débora Ribeiro Orlando, Alan Rodrigues Teixeira Machado, Bruno Del Bianco Borges, Luciano José Pereira, Marco Fabrício Dias‐Peixoto, Eric Francelino Andrade   +9 more
wiley   +1 more source

Burden of Herpes Zoster Among Patients with Psoriatic Arthritis in the United States [PDF]

David Singer,1 Philippe Thompson-Leduc,2 Siyu Ma,1,3 Deepshekhar Gupta,4 Wendy Y Cheng,5 Selvam R Sendhil,6 Manasvi Sundar,6 Ella Hagopian,5 Nikita Stempniewicz,1 Mei Sheng Duh,5 Sara Poston1 1GSK, US Health Economics and Outcomes Research, Philadelphia,
Gupta D, Ma S, Cheng WY, Stempniewicz N, Duh MS, Poston S, Thompson-Leduc P, Sundar M, Hagopian E, Sendhil SR, Singer D   +10 more
core   +1 more source

Vasculitis associated with psoriatic arthritis: a case report

Egyptian Rheumatology and Rehabilitation
Background Psoriatic arthritis is a chronic inflammatory condition associated with psoriasis, which affects joints. The coexistence of vasculitis, an inflammation of blood vessels, with psoriatic arthritis is rare, highlighting a complex interplay ...
Mehdi Jafarpour, Bita Rahbari, Bahareh Mehramuz, Sara Daneshvar   +3 more
doaj   +1 more source